Detailed Narrative
Nuclear Power Market Tailwinds and Demand Acceleration
Mirion is benefiting from significant tailwinds in the Nuclear Power market, driven by increasing energy demand and geopolitical events. The DOE's UPRISE initiative aims to boost existing U.S. nuclear capacity by 2.5 gigawatts by 2027 and 5 gigawatts by 2029. The Trump administration's broader push targets expanding U.S. nuclear capacity from 100 gigawatts to 400 gigawatts by 2050. These initiatives, coupled with utilities committing $1.4 trillion in planned capital expenditures through 2030 (a 21% increase from a year ago), underscore a robust and accelerating demand for nuclear energy, independent of AI growth.
Paragon and Certrec Integration Success
The acquisitions of Paragon and Certrec are strategically positioning Mirion to address the U.S. nuclear market effectively. Paragon's Q1 revenue grew 45%, reflecting broad-based demand. The integration is progressing well, with identified additional synergy opportunities and strong collaboration between legacy teams. Commercial synergies are materializing faster than anticipated, with joint customer engagements already resulting in incremental order wins, leveraging Paragon's relationships to secure orders for legacy Mirion products.
Significant Backlog Expansion and Order Momentum
Strong order generation in Q4 FY25 and Q1 FY26 has led to a step change in Mirion's backlog, which now totals $1.1 billion, up 38% including M&A. Orders increased 19% organically to $241 million in Q1, or 42% including M&A to $288 million. This expanding backlog is a precursor to accelerated revenue growth, with management noting that large orders are occurring earlier in the year, providing better visibility into 2026 and 2027 revenue opportunities. An additional $35 million in SMR-related orders was secured in April.
Medical Segment Recovery and Growth Drivers
The Medical segment is showing promising signs of recovery. The RTQA end market posted double-digit organic revenue growth in Q1, driven by an easier comparable, favorable software performance, and a significant radiation-tolerant camera order tied to the Varian partnership. Nuclear Medicine remains on track for its second consecutive year of double-digit organic revenue growth in 2026, supported by its market-leading position and the growing radiopharma ecosystem. Dosimetry Services continues to be a reliable franchise with strong margins.
Installed Base Modernization and SMR Opportunities
The psychology of nuclear plant operators has shifted from defensive postures to long-term operating cycles, with many aiming for 100-year lifespans. This change profoundly impacts capital spending plans, driving demand for modernization, instrumentation and control (I&C) upgrades, and digitally enabled radiation protection solutions. Over 80% of Mirion's Nuclear Power revenue comes from the installed base. Additionally, the company is bullish on the advanced reactor market, securing approximately $15 million in SMR orders in Q1 and an additional $35 million in April, with strong engagement across leading SMR players.
Long-Term Margin Expansion and AI Investment
Mirion reiterated its target of achieving a 30% adjusted EBITDA margin by 2028. While Q1 saw margin contraction due to M&A and mix shifts, management expects margin expansion in the legacy business in subsequent quarters. The path to the 30% target involves volume absorption against a fixed cost structure and self-help initiatives, including procurement, conversion processes, and pricing heuristics. Significant investment in AI is also underway, which is currently margin-dilutive but expected to drive future cost and efficiency improvements, as well as new product solutions.